Areas of Focus

Addressing Large Unmet Needs for
Patients with Chronic Respiratory Diseases

ProterixBio is currently developing chronic care platforms for pulmonary diseases, with an initial focus on COPD. Additional areas of pulmonary research include CF (cystic fibrosis) and IPF (idiopathic pulmonary fibrosis). Chronic pulmonary diseases share some common disease processes. ProterixBio’s development strategy leverages this commonality in the design of our biomarker panels, clinical studies, and data analysis methods.


Multifaceted Pulmonary Diseases

Distinct Causes – Common Pathways

Statistics below are for the US only

COPD Chronic Obstructive Pulmonary Disease

  • 11-13MM Diagnosed
  • 3rd Leading Cause of Death
  • $38B Cost 2012 >> $50B 2020
  • >50% of Direct Costs Due to Exacerbations
  • 20-25% 30-Day Hospital Readmission Rate

IPF Idiopathic Pulmonary Fibrosis

  • 106,000 Diagnosed
  • Median Survival 3-5 years

CF Cystic Fibrosis

  • 30,000 Diagnosed
  • Average Lifespan 37-40 years

Learn More About our Areas of Focus: